Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice

References

• Mogensen M, Morsy HA, Thrane L, Jemec GB. Morphology and epidermal thickness of normal skin imaged by optical coherence tomography. Dermatology217(1), 14–20 (2008).
   PubMed Web of Science ®Google Scholar
• Kissenpfennig A, Malissen B. Langerhans cells–revisiting the paradigm using genetically engineered mice. Trends Immunol.27(3), 132–139 (2006).
   PubMed Web of Science ®Google Scholar
• Steinman RM. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol.9, 271–296 (1991).
   PubMed Web of Science ®Google Scholar
• Phan TG, Grigorova I, Okada T, Cyster JG. Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells. Nat. Immunol.8(9), 992–1000 (2007).
   PubMed Web of Science ®Google Scholar
• Rossi M, Young JW. Human dendritic cells, potent antigen-presenting cells at the crossroads of innate and adaptive immunity. J. Immunol.175(3), 1373–1381 (2005).
   PubMed Web of Science ®Google Scholar
• Adler HS, Steinbrink K. Tolerogenic dendritic cells in health and disease: friend and foe! Eur. J. Dermatol.17(6), 476–491 (2007).
   PubMed Web of Science ®Google Scholar
• Valladeau J, Saeland S. Cutaneous dendritic cells. Semin. Immunol.17(4), 273–283 (2005).
   PubMed Web of Science ®Google Scholar
• Poulin LF, Henri S, de Bovis B, Devilard E, Kissenpfennig A, Malissen B. The dermis contains langerin+ dendritic cells that develop and function independently of epidermal Langerhans cells. J. Exp. Med.204(13), 3119–3131 (2007).
   PubMed Web of Science ®Google Scholar
• Mathers AR, Larregina AT. Professional antigen-presenting cells of the skin. Immunol. Res.36(1–3), 127–136 (2006).
   PubMed Web of Science ®Google Scholar
• Ginhoux F, Collin MP, Bogunovic M et al. Blood-derived dermal langerin+ dendritic cells survey the skin in the steady state. J. Exp. Med.204(13), 3133–3146 (2007).
   PubMed Web of Science ®Google Scholar
• Flacher V, Bouschbacher M, Verronese E et al. Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria. J. Immunol.177(11), 7959–7967 (2006).
   PubMed Web of Science ®Google Scholar
• van der Aar AM, Sylva-Steenland RM, Bos JD, Kapsenberg ML, de Jong EC, Teunissen MB. Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition. J. Immunol.178(4), 1986–1990 (2007).
   PubMed Web of Science ®Google Scholar
• Villadangos JA, Schnorrer P. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo . Nat. Rev. Immunol.7(7), 543–555 (2007).
   PubMed Web of Science ®Google Scholar
• Kissenpfennig A, Henri S, Dubois B et al. Dynamics and function of Langerhans cells in vivo : dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity22(5), 643–654 (2005).
   PubMed Web of Science ®Google Scholar
• Kaplan DH, Jenison MC, Saeland S, Shlomchik WD, Shlomchik MJ. Epidermal langerhans cell-deficient mice develop enhanced contact hypersensitivity. Immunity23(6), 611–620 (2005).
   PubMed Web of Science ®Google Scholar
• Bennett CL, van Rijn E, Jung S et al. Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity. J. Cell. Biol.169(4), 569–576 (2005).
   PubMed Web of Science ®Google Scholar
• Stoecklinger A, Grieshuber I, Scheiblhofer S et al. Epidermal langerhans cells are dispensable for humoral and cell-mediated immunity elicited by gene gun immunization. J. Immunol.179(2), 886–893 (2007).
   PubMed Web of Science ®Google Scholar
• Etchart N, Hennino A, Friede M et al. Safety and efficacy of transcutaneous vaccination using a patch with the live-attenuated measles vaccine in humans. Vaccine25(39–40), 6891–6899 (2007).
   PubMed Web of Science ®Google Scholar
• Ueno H, Klechevsky E, Morita R et al. Dendritic cell subsets in health and disease. Immunol. Rev.219, 118–142 (2007).
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Wagner M, Gunther S et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J. Invest. Dermatol.119(5), 1096–1102 (2002).
   PubMed Web of Science ®Google Scholar
• Le Borgne M, Etchart N, Goubier A et al. Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo . Immunity24(2), 191–201 (2006).
   PubMed Web of Science ®Google Scholar
• Morelli AE, Rubin JP, Erdos G et al. CD4+T cell responses elicited by different subsets of human skin migratory dendritic cells. J. Immunol.175(12), 7905–7915 (2005).
   PubMed Web of Science ®Google Scholar
• Pena-Cruz V, Ito S, Dascher CC, Brenner MB, Sugita M. Epidermal Langerhans cells efficiently mediate CD1a-dependent presentation of microbial lipid antigens to T cells. J. Invest. Dermatol.121(3), 517–521 (2003).
   PubMed Web of Science ®Google Scholar
• Hwang ST. Mechanisms of T-cell homing to skin. Adv. Dermatol.17, 211–241 (2001).
   PubMedGoogle Scholar
• Schroder JM, Mochizuki M. The role of chemokines in cutaneous allergic inflammation. Biol. Chem.380(7–8), 889–896 (1999).
   PubMed Web of Science ®Google Scholar
• Glenn GM, Kenney RT, Ellingsworth LR, Frech SA, Hammond SA, Zoeteweij JP. Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin. Expert Rev. Vaccines2(2), 253–267 (2003).
   PubMed Web of Science ®Google Scholar
• Chen D, Maa YF, Haynes JR. Needle-free epidermal powder immunization. Expert Rev. Vaccines1(3), 265–276 (2002).
   PubMedGoogle Scholar
• Gretz JE, Norbury CC, Anderson AO, Proudfoot AE, Shaw S. Lymph-borne chemokines and other low molecular weight molecules reach high endothelial venules via specialized conduits while a functional barrier limits access to the lymphocyte microenvironments in lymph node cortex. J. Exp. Med.192(10), 1425–1440 (2000).
   PubMed Web of Science ®Google Scholar
• Reddy ST, van der Vlies AJ, Simeoni E et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol.25(10), 1159–1164 (2007).
   PubMed Web of Science ®Google Scholar
• Iezzi G, Frohlich A, Ernst B et al. Lymph node resident rather than skin-derived dendritic cells initiate specific T cell responses after Leishmania major infection. J. Immunol.177(2), 1250–1256 (2006).
   PubMed Web of Science ®Google Scholar
• Allan RS, Smith CM, Belz GT et al. Epidermal viral immunity induced by CD8α+ dendritic cells but not by Langerhans cells. Science301(5641), 1925–1928 (2003).
   PubMed Web of Science ®Google Scholar
• Allan RS, Waithman J, Bedoui S et al. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity25(1), 153–162 (2006).
   PubMed Web of Science ®Google Scholar
• Sixt M, Kanazawa N, Selg M et al. The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. Immunity22(1), 19–29 (2005).
   PubMed Web of Science ®Google Scholar
• Abadie V, Badell E, Douillard P et al. Neutrophils rapidly migrate via lymphatics after Mycobacterium bovis BCG intradermal vaccination and shuttle live bacilli to the draining lymph nodes. Blood106(5), 1843–1850 (2005).
   PubMed Web of Science ®Google Scholar
• Itano AA, McSorley SJ, Reinhardt RL et al. Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity19(1), 47–57 (2003).
   PubMed Web of Science ®Google Scholar
• Maloy KJ, Erdmann I, Basch V et al. Intralymphatic immunization enhances DNA vaccination. Proc. Natl Acad. Sci. USA98(6), 3299–3303 (2001).
   PubMed Web of Science ®Google Scholar
• Johansen P, Haffner AC, Koch F et al. Direct intralymphatic injection of peptide vaccines enhances immunogenicity. Eur. J. Immunol.35(2), 568–574 (2005).
   PubMed Web of Science ®Google Scholar
• Oussoren C, Storm G. Liposomes to target the lymphatics by subcutaneous administration. Adv. Drug. Deliv. Rev.50(1–2), 143–156 (2001).
   PubMed Web of Science ®Google Scholar
• Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine26(26), 3197–3208 (2008).
   PubMed Web of Science ®Google Scholar
• Glenn GM, Kenney RT. Mass vaccination: solutions in the skin. Curr. Top. Microbiol. Immunol.304, 247–268 (2006).
   PubMed Web of Science ®Google Scholar
• Kenney RT, Yu J, Guebre-Xabier M et al. Induction of protective immunity against lethal anthrax challenge with a patch. J. Infect. Dis.190(4), 774–782 (2004).
   PubMed Web of Science ®Google Scholar
• Frech SA, Kenney RT, Spyr CA et al. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. Vaccine23(7), 946–950 (2005).
   PubMed Web of Science ®Google Scholar
• Widera G, Johnson J, Kim L et al. Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system. Vaccine24(10), 1653–1664 (2006).
   PubMed Web of Science ®Google Scholar
• Vogt A, Mahe B, Costagliola D et al. Transcutaneous anti-influenza vaccination promotes both CD4 and CD8 T cell immune responses in humans. J. Immunol.180(3), 1482–1489 (2008).
   PubMed Web of Science ®Google Scholar
• Dean HJ, Chen D. Epidermal powder immunization against influenza. Vaccine23(5), 681–686 (2004).
   PubMed Web of Science ®Google Scholar
• Roberts LK, Barr LJ, Fuller DH, McMahon CW, Leese PT, Jones S. Clinical safety and efficacy of a powdered hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device. Vaccine23(40), 4867–4878 (2005).
   PubMed Web of Science ®Google Scholar
• Lu S, Wang S, Grimes-Serrano JM. Current progress of DNA vaccine studies in humans. Expert Rev. Vaccines7(2), 175–191 (2008).
   PubMed Web of Science ®Google Scholar
• WHO Expert consultation on rabies. World Health Organ. Tech. Rep. Ser.931, 1–88 (2005).
   PubMed Web of Science ®Google Scholar
• Vien NC, Feroldi E, Lang J. Long-term anti-rabies antibody persistence following intramuscular or low-dose intradermal vaccination of young Vietnamese children. Trans. R. Soc. Trop. Med. Hyg.102(3), 294–296 (2008).
   PubMed Web of Science ®Google Scholar
• Suwansrinon K, Wilde H, Benjavongkulchai M et al. Survival of neutralizing antibody in previously rabies vaccinated subjects: a prospective study showing long lasting immunity. Vaccine24(18), 3878–3880 (2006).
   PubMed Web of Science ®Google Scholar
• Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N. Engl. J. Med.351(22), 2295–2301 (2004).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Newman FK, Cannon J et al. Serum antibody responses after intradermal vaccination against influenza. N. Engl. J. Med.351(22), 2286–2294 (2004).
   PubMed Web of Science ®Google Scholar
• Belshe RB, Newman FK, Wilkins K et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine25(37–38), 6755–6763 (2007).
   PubMed Web of Science ®Google Scholar
• Micozkadioglu H, Zumrutdal A, Torun D, Sezer S, Ozdemir FN, Haberal M. Low dose intradermal vaccination is superior to high dose intramuscular vaccination for hepatitis B in unresponsive hemodialysis patients. Ren. Fail.29(3), 285–288 (2007).
   PubMed Web of Science ®Google Scholar
• Ponvert C, Scheinmann P. Vaccine allergy and pseudo-allergy. Eur. J. Dermatol.13(1), 10–15 (2003).
   PubMed Web of Science ®Google Scholar
• Vial T, Descotes J. Autoimmune diseases and vaccinations. Eur. J. Dermatol.14(2), 86–90 (2004).
   PubMed Web of Science ®Google Scholar
• Kemp EB, Belshe RB, Hoft DF. Immune responses stimulated by percutaneous and intradermal bacille Calmette–Guerin. J. Infect. Dis.174(1), 113–119 (1996).
   PubMed Web of Science ®Google Scholar
• Relyveld EH, Bizzini B, Gupta RK. Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids. Vaccine16(9–10), 1016–1023 (1998).
   PubMed Web of Science ®Google Scholar
• Anjuere F, George-Chandy A, Audant F, Rousseau D, Holmgren J, Czerkinsky C. Transcutaneous immunization with cholera toxin B subunit adjuvant suppresses IgE antibody responses via selective induction of Th1 immune responses. J. Immunol.170(3), 1586–1592 (2003).
   PubMed Web of Science ®Google Scholar
• Shepard CC, Walker LL, Van Landingham RM, Ye SZ. Sensitization or tolerance to Mycobacterium leprae antigen by route of injection. Infect. Immun.38(2), 673–680 (1982).
   PubMed Web of Science ®Google Scholar
• George A, Shroff KE, Rath S, Ghosh SN, Sengupta SR, Kamat RS. Route-related variation in the immunogenicity of killed Salmonella enteritidis vaccine: role of antigen presenting cells. Microbiol. Immunol.33(6), 479–488 (1989).
   PubMed Web of Science ®Google Scholar
• Campton K, Ding W, Yan Z et al. Tumor antigen presentation by dermal antigen-presenting cells. J. Invest. Dermatol.115(1), 57–61 (2000).
   PubMed Web of Science ®Google Scholar
• Zhao X, Deak E, Soderberg K et al. Vaginal submucosal dendritic cells, but not Langerhans cells, induce protective Th1 responses to herpes simplex virus-2. J. Exp. Med.197(2), 153–162 (2003).
   PubMed Web of Science ®Google Scholar
• Pertmer TM, Roberts TR, Haynes JR. Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J. Virol.70(9), 6119–6125 (1996).
   PubMed Web of Science ®Google Scholar
• Streit M, Braathen LR. Contact dermatitis: clinics and pathology. Acta Odontol. Scand.59(5), 309–314 (2001).
   PubMed Web of Science ®Google Scholar
• Beck JS. Skin changes in the tuberculin test. Tubercle72(2), 81–87 (1991).
   PubMedGoogle Scholar
• Nagafuchi S, Kashiwagi S, Okada K et al. Reversal of nonresponders and postexposure prophylaxis by intradermal hepatitis B vaccination in Japanese medical personnel. JAMA265(20), 2679–2683 (1991).
   PubMed Web of Science ®Google Scholar
• Nagafuchi S, Kashiwagi S, Hayashi J, Katsuta H, Ikematsu H, Harada M. A delayed type hypersensitivity (DTH) skin reaction to hepatitis B surface antigen (HBsAg) and intradermal hepatitis B vaccination. Fukuoka Igaku Zasshi95(12), 305–313 (2004).
   PubMedGoogle Scholar
• Barone P, Sciacca A, Lupo F, Leonardi S, Musumeci S. Hepatitis B vaccination in young nurses of a general hospital. Ann. Ig.7(4), 251–255 (1995).
   PubMedGoogle Scholar
• Rudin C, Gunthard J, Halter C, Staehelin J, Berglund A. Anaphylactoid reaction to BCG vaccine containing high molecular weight dextran. Eur. J. Pediatr.154(11), 941–942 (1995).
   PubMed Web of Science ®Google Scholar
• Ponnighaus JM, Fine PE, Moreno C. Hypersensitivity to dextran in BCG vaccine. Lancet337(8748), 1039 (1991)
   PubMedGoogle Scholar
• Becker CE, McGregor RR, Walker KS, Jandle JH. Fatal anaphylaxis after intra-muscular iron-dextran. Ann. Int. Med.65, 745–748 (1966)
   PubMed Web of Science ®Google Scholar
• Khawplod P, Wilde H, Benjavongkulchai M, Sriaroon C, Chomchey P. Immunogenicity study of abbreviated rabies pre-exposure vaccination schedules. J. Travel Med.14(3), 173–176 (2007).
   PubMed Web of Science ®Google Scholar
• Sudarshan MK, Madhusudana SN, Mahendra BJ et al. Boosting effect of purified chick embryo cell rabies vaccine using the intradermal route in persons previously immunized by the intramuscular route or vice versa.Natl Med. J. India19(4), 192–194 (2006).
   PubMed Web of Science ®Google Scholar
• Lang J, Hoa DQ, Gioi NV et al. Immunogenicity and safety of low-dose intradermal rabies vaccination given during an expanded programme on immunization session in Vietnam: results of a comparative randomized trial. Trans. R. Soc. Trop. Med. Hyg.93(2), 208–213 (1999).
   PubMed Web of Science ®Google Scholar
• Sabchareon A, Chantavanich P, Pasuralertsakul S et al. Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations with purified Vero cell rabies vaccine. Pediatr. Infect. Dis. J.17(11), 1001–1007 (1998).
   PubMed Web of Science ®Google Scholar
• Jaiiaroensup W, Lang J, Thipkong P et al. Safety and efficacy of purified Vero cell rabies vaccine given intramuscularly and intradermally. (Results of a prospective randomized trial). Vaccine16(16), 1559–1562 (1998).
   PubMed Web of Science ®Google Scholar
• Charanasri U, Meesomboon V, Kingnate D, Samuthananont P, Chaeychomsri W. Intradermal simulated rabies postexposure prophylaxis using purified chick embryo rabies vaccine. J. Med. Assoc. Thai.77(3), 157–160 (1994).
   PubMedGoogle Scholar
• Ratanavongsiri J, Sriwanthana B, Ubol S, Phanuphak P. Cell-mediated immune response following intracutaneous immunisation with human diploid cell rabies vaccine. Asian Pac. J. Allergy Immunol.3(2), 187–190 (1985).
   PubMed Web of Science ®Google Scholar
• Grandien M, Fridell E, Kindmark CO. Intradermal immunization with reduced doses of human diploid cell strain rabies vaccine: evaluation of antibody response by ELISA and mixed hemadsorption test. Scand. J. Infect. Dis.17(2), 173–178 (1985).
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Turner GS, Aoki FY. Immunization with a human diploid cell strain of rabies virus vaccine: two-year results. J. Infect. Dis.137(6), 783–788 (1978).
   PubMed Web of Science ®Google Scholar
• Cox JH, Schneider LG. Prophylactic immunization of humans against rabies by intradermal inoculation of human diploid cell culture vaccine. J. Clin. Microbiol.3(2), 96–101 (1976).
   PubMed Web of Science ®Google Scholar
• Chiu SS, Peiris JS, Chan KH, Wong WH, Lau YL. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. Pediatrics119(6), 1076–1082 (2007).
   PubMed Web of Science ®Google Scholar
• Auewarakul P, Kositanont U, Sornsathapornkul P et al. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine25(4), 659–663 (2007).
   PubMed Web of Science ®Google Scholar
• Khanlou H, Sanchez S, Babaie M et al. The safety and efficacy of dose-sparing intradermal administration of influenza vaccine in human immunodeficiency virus-positive patients. Arch. Intern. Med.166(13), 1417 (2006).
   PubMed Web of Science ®Google Scholar
• Herbert FA, Larke RP, Markstad EL. Comparison of responses to influenza A/New Jersey/76-A/Victoria/75 virus vaccine administered intradermally or subcutaneously to adults with chronic respiratory disease. J. Infect. Dis.140(2), 234–238 (1979).
   PubMed Web of Science ®Google Scholar
• Halperin W, Weiss WI, Altman R et al. A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 (swine flu) and A/Victoria/75: report of a study and review of the literature. Am. J. Public Health69(12), 1247–1251 (1979).
   PubMed Web of Science ®Google Scholar
• Brown H, Kasel JA, Freeman DM et al. The immunizing effect of influenza A/New Jersey/76 (Hsw1N1) virus vaccine administered intradermally and intramuscularly to adults. J. Infect. Dis.136(Suppl.), S466–S471 (1977).
   PubMed Web of Science ®Google Scholar
• Chanchairujira T, Chantaphakul N, Thanwandee T, Ong-Ajyooth L. Efficacy of intradermal hepatitis B vaccination compared to intramuscular vaccination in hemodialysis patients. J. Med. Assoc .Thai.89(Suppl. 2), S33–S40 (2006).
   PubMedGoogle Scholar
• Roozbeh J, Moini M, Lankarani KB et al. Low dose intradermal versus high dose intramuscular hepatitis B vaccination in patients on chronic hemodialysis. ASAIO J.51(3), 242–245 (2005).
   PubMed Web of Science ®Google Scholar
• Ghabouli MJ, Sabouri AH, Shoeibi N, Bajestan SN, Baradaran H. High seroprotection rate induced by intradermal administration of a recombinant hepatitis B vaccine in young healthy adults: comparison with standard intramuscular vaccination. Eur. J. Epidemiol.19(9), 871–875 (2004).
   PubMed Web of Science ®Google Scholar
• Chau KF, Cheng YL, Tsang DN et al. Efficacy and side effects of intradermal hepatitis B vaccination in CAPD patients: a comparison with the intramuscular vaccination. Am. J. Kidney Dis.43(5), 910–917 (2004).
   PubMed Web of Science ®Google Scholar
• Gomber S, Sharma R, Ramachandran VG. Immunogenicity of low dose intradermal hepatitis B vaccine and its comparison with standard dose intramuscular vaccination. Indian Pediatr.41(9), 922–926 (2004).
   PubMedGoogle Scholar
• Somboonsilp W, Eiam-Ong S, Tungsanga K, Tirawatanapong T. Immune response of intradermal hepatitis B vaccination at lower dose versus intramuscular vaccination at double standard dose in predialytic chronic renal failure patients. J. Med. Assoc. Thai.86(12), 1122–1127 (2003).
   PubMedGoogle Scholar
• Lankarani KB, Taghavi AR, Agah S, Karimi A. Comparison of intradermal and intramuscular administration of hepatitis B vaccine in neonates. Indian J. Gastroenterol.20(3), 94–96 (2001).
   PubMedGoogle Scholar
• Henderson EA, Louie TJ, Ramotar K, Ledgerwood D, Hope KM, Kennedy A. Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers. Infect. Control Hosp. Epidemiol.21(4), 264–269 (2000).
   PubMed Web of Science ®Google Scholar
• Vlassopoulos DA, Arvanitis DK, Lilis DS, Louizou KI, Hadjiconstantinou VE. Lower long-term efficiency of intradermal hepatitis B vaccine compared to the intramuscular route in hemodialysis patients. Int. J. Artif. Organs22(11), 739–743 (1999).
   PubMed Web of Science ®Google Scholar
• Egemen A, Aksit S, Kurugol Z, Erensoy S, Bilgic A, Akilli M. Low-dose intradermal versus intramuscular administration of recombinant hepatitis B vaccine: a comparison of immunogenicity in infants and preschool children. Vaccine16(16), 1511–1515 (1998).
   PubMed Web of Science ®Google Scholar
• Turchi MD, Martelli CM, Ferraz ML et al. Immunogenicity of low-dose intramuscular and intradermal vaccination with recombinant hepatitis B vaccine. Rev. Inst. Med. Trop. Sao Paulo39(1), 15–19 (1997).
   PubMedGoogle Scholar
• Hayashi J, Nakashima K, Noguchi A, Morofuji M, Kashiwagi S. Cost effectiveness of intradermal vs. subcutaneous hepatitis B vaccination for the mentally handicapped. J. Infect.23(1), 39–45 (1991).
   PubMed Web of Science ®Google Scholar
• Toffler WL, Olenick JS, Wolf NE, Retzlaff ZH, Swanson JR, Kenny TA. The immunogenicity and safety of intradermal hepatitis B vaccine. J. Fam. Pract.33(2), 149–154 (1991).
   PubMed Web of Science ®Google Scholar
• King JW, Taylor EM, Crow SD et al. Comparison of the immunogenicity of hepatitis B vaccine administered intradermally and intramuscularly. Rev. Infect. Dis.12(6), 1035–1043 (1990).
   PubMedGoogle Scholar
• Gonzalez ML, Usandizaga M, Alomar P et al. Intradermal and intramuscular route for vaccination against hepatitis B. Vaccine8(4), 402–405 (1990).
   PubMed Web of Science ®Google Scholar
• Frazer IH, Jones B, Dimitrakakis M, Mackay IR. Intramuscular versus low-dose intradermal hepatitis B vaccine. Assessment by humoral and cellular immune response to hepatitis B surface antigen. Med. J. Aust.146(5), 242–245 (1987).
   PubMed Web of Science ®Google Scholar
• Herbert M, Butler AV, Roome AP, Caul EO. Comparison of intradermal and intramuscular hepatitis B vaccination in university students. Vaccine7(5), 395–396 (1989).
   PubMed Web of Science ®Google Scholar
• Milne A. Intramuscular versus intradermal hepatitis B vaccination. NZ Med. J.99(808), 640 (1986)
   PubMedGoogle Scholar
• Halsey NA, Reppert EJ, Margolis HS, Francis DP, Fields HA. Intradermal hepatitis B vaccination in an abbreviated schedule. Vaccine4(4), 228–232 (1986).
   PubMed Web of Science ®Google Scholar
• Pancharoen C, Mekmullica J, Thisyakorn U et al. Reduced-dose intradermal vaccination against hepatitis A with an aluminum-free vaccine is immunogenic and can lower costs. Clin. Infect. Dis.41(10), 1537–1540 (2005).
   PubMed Web of Science ®Google Scholar
• Mikulska-Skupien E, Szweda W, Procajlo Z. Evaluation of specific humoral immune response in pigs vaccinated intradermally with deleted Aujeszky’s disease vaccine and challenged with virulent strain of Herpesvirus suis type 1. Pol. J. Vet. Sci.8(1), 11–16 (2005).
   PubMedGoogle Scholar
• Grosenbaugh DA, Leard T, Pardo MC, Motes-Kreimeyer L, Royston M. Comparison of the safety and efficacy of a recombinant feline leukemia virus (FeLV) vaccine delivered transdermally and an inactivated FeLV vaccine delivered subcutaneously. Vet. Ther.5(4), 258–262 (2004).
   PubMed Web of Science ®Google Scholar